mutation class

Copy Number Variant

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

267 sites for NCT03994796

AKT1 Amplification, +52 more biomarkers

Malignant Solid Tumor

abemaciclib, +2 more drugs

targeted therapy

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

10 sites for NCT03297606

ABL1 Fusion, +98 more biomarkers

B-Cell Non-Hodgkin Lymphoma, +2 more conditions

axitinib, +15 more drugs

immunotherapy, +1 more type

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

35 sites for NCT04591431

AKT1 Amplification, +59 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +19 more drugs

immunotherapy, +1 more type

CRAFT: The NCT-PMO-1602 Phase II Trial

4 sites for NCT04551521

AKT1 Amplification, +78 more biomarkers

Malignant Solid Tumor

alectinib, +6 more drugs

immunotherapy, +1 more type

A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

9 sites for NCT04958226

AKT1 Amplification, +8 more biomarkers

Malignant Solid Tumor

capivasertib, +1 more drug

Other, +1 more type

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

1 site for NCT04849364

AKT1 Amplification, +141 more biomarkers

Invasive Breast Carcinoma

atezolizumab, +3 more drugs

chemotherapy, +2 more types